Biologic Basics: The Type 2 Connection (AAN)
Price: FREE for members and non-members
Session recorded on August 25, 2022
Speaker: Jim Tracy, MD
Description: The number of biological therapies is rapidly evolving within the allergy disease space. Historically, TH2 inflammation is a pivotal component of both the disease state as well as therapeutic opportunities. Most clinicians lack an understanding of the historical context and development of these strategies. the number of biological therapies and the precise strategy to implementation is sometimes lost.
Viewers can earn credit by completing the posttest questions.
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this activity learners should be able to:
- Review the basics of T-cell subset development
- Have a working knowledge of currently available biological therapies for allergic disease
- Assess the place each biological holds within the allergy disease space
All relevant finaicial relationships have been mitigated.
Michael Blaiss, MD, FACAAI Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Jim Tracy, MD, FACAAI Speaker
Disclosures: Advisor: Genentec, Thermo-Fischer, Novartis, Hollister-Stier
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance